Overview of Tafirol Flex

Tafirol Flex is a Fixed-Dose Combination (FDC) medicine, classified as an analgesic miorrelaxant, administered via the oral route. This dual-action preparation is designed to address simultaneous discomfort from both pain and muscle stiffness. Tafirol Flex is primarily recognized in markets such as Mexico and Central America and is typically positioned for managing acute painful musculoskeletal conditions in adults.

Property	Description
Active Ingredients	Acetaminophen/Paracetamol, Chlorzoxazone
Form	Tablet (Solid, oral dosage form)
Pharmacological Class	Skeletal Muscle Relaxant and Analgesic (Combination Product)
General Purpose	Symptomatic relief of pain complicated by muscle spasm
Origin	Synthetic

What Type of Medicine is Tafirol Flex?

Tafirol Flex is structured as an FDC product, containing two different active substances in a single unit. This classification as an analgesic miorrelaxant sets it apart from simple, single-agent pain relievers or muscle relaxants by providing a comprehensive approach to managing both components of musculoskeletal discomfort. The medicine is based on two synthetic agents and is taken orally as a solid tablet. This combination approach targets the dual pathology of pain and spasm in conditions like low back discomfort.

What are the Active Ingredients in Tafirol Flex?

The primary active ingredients in Tafirol Flex are Acetaminophen (also known as Paracetamol) and Chlorzoxazone. Acetaminophen functions as the non-opioid analgesic and antipyretic component, mainly acting within the central nervous system to modulate pain perception. The inclusion of Chlorzoxazone serves as the centrally acting muscle relaxant, whose mechanism involves acting on nerve pathways in the spinal cord to inhibit the reflexes that cause muscle spasm and stiffness. The combined action of these two components is designed to provide simultaneous relief from pain and muscle tension.

What is the General Purpose of Tafirol Flex?

The general purpose of Tafirol Flex is to alleviate the symptoms associated with painful musculoskeletal conditions where involuntary muscle rigidity is present. By combining analgesic action (pain relief) with myorelaxant action (muscle relaxation), the preparation helps interrupt the cycle where pain triggers spasm, which, in turn, worsens the pain. This dual approach is intended to restore comfort and ease muscle tension.

Regulatory References

Chlorzoxazone Mechanism and Status, NIH LiverTox

What side effects are possible with Tafirol Flex?

Possible Side Effects and Safety Information

The safety profile of Tafirol Flex, a fixed-dose combination of Acetaminophen (Paracetamol) and Chlorzoxazone, is defined by the officially documented risks of its two active ingredients. This information is classified and communicated according to regulatory standards, distinguishing between frequent, expected effects and rare, serious constraints.

Adverse Reaction Scope

Component	Adverse Reaction Category	Frequency Classification
Chlorzoxazone	Central Nervous System (CNS) Effects	Occasional/Expected
Chlorzoxazone	Gastrointestinal Effects	Occasional
Both	Hepatotoxicity (Liver Damage)	Dose-dependent (Acetaminophen) / Rare (Chlorzoxazone)

The most frequently observed adverse reactions are generally associated with the Chlorzoxazone component and include effects on the Nervous System, such as drowsiness, dizziness, and lightheadedness. Gastrointestinal disturbances like nausea or epigastric distress are also listed as occasional.

Serious Adverse Reactions and Safety Constraints

The most critical regulatory safety domain involves the potential for Hepatotoxicity (liver damage). Serious adverse reactions include Acute Liver Failure from the Acetaminophen component (especially when maximum daily dose is exceeded) and Severe Hepatocellular Toxicity, which has been rarely reported with Chlorzoxazone. Both active agents are associated with rare but potentially severe Allergic and Skin Reactions.

Population-Specific and Contextual Restrictions are officially documented. The medicine is contraindicated in patients with severe hepatic impairment. There is a heightened risk of liver damage from Acetaminophen for individuals who consume three or more alcoholic drinks per day. Furthermore, the safe use of Chlorzoxazone has not been established for the pediatric population or during pregnancy and lactation. Concomitant use with alcohol or other central nervous system depressants may produce an additive CNS depressant effect, a high-level safety constraint defined in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Tafirol Flex, a fixed-dose combination of Acetaminophen (Paracetamol) and Chlorzoxazone, requires immediate medical attention according to official regulatory mandates, even when a patient is initially asymptomatic. This is crucial due to the potential for delayed, life-threatening acute liver failure and hepatic necrosis caused by the Acetaminophen component.

Initial documented manifestations of overdose may include nausea, vomiting, abdominal pain, paleness, and sweating. Later signs of hepatotoxicity can progress to jaundice, dark urine, and confusion. Overdose of the Chlorzoxazone component acutely presents with central nervous system (CNS) depression, characterized by drowsiness, severe loss of muscle tone, and depressed reflexes, which can lead to respiratory depression and hypotension.

Regulatory documentation confirms the availability of a specific antidote (N-acetylcysteine) for the Acetaminophen component. Management often involves supportive treatment, gastric decontamination procedures, and continuous monitoring of plasma drug levels and liver function. Patients with pre-existing hepatic impairment or alcoholism are identified in official labeling as being at an increased risk for severe overdose outcomes.

Therapeutic Uses of Tafirol Flex

Tafirol Flex is used in areas where short-term symptom management is appropriate when symptoms related to physical discomfort are accompanied by muscle tension. Its use supports the patient during difficult episodes by easing distress and is relevant in conditions associated with acute or disruptive episodes.

Relief for Acute Painful Muscle Spasms

This combination medication is commonly used across conditions presenting with acute episodes where involuntary muscle contractures are a primary source of discomfort. Such conditions may include low back pain (lumbalgia), neck stiffness (torticollis), and painful spasms arising from muscle strains or minor traumatic injuries. The muscle relaxant component is applied to help with pain and stiffness caused by muscle strains and sprains. It is applied when symptoms create noticeable functional strain, helping to ease the challenging manifestations of intense muscle rigidity.

Management of the Pain and Muscle Tension Cluster

The primary therapeutic benefit is that this combination product helps address symptom clusters where both pain and muscle tension occur together. This supports the patient during difficult episodes by easing distress related to the interdependent nature of pain and spasm. This contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Relief for Pain and Muscle Spasm
Symptom Cluster: Dual management of pain (analgesia) and involuntary muscle rigidity (miorelaxation).
Scenario: Conditions marked by periods of heightened symptoms, such as acute low back pain.

Regulatory References

NIH MedlinePlus overview of Chlorzoxazone

Eligibility and Restrictions for Use

Tafirol Flex is an analgesic miorrelaxant combination whose official use is strictly defined by regulatory documentation across several key population groups. The population-eligibility criteria establish formal restrictions and absolute non-eligibility for various users.

Eligibility Status	Defined Population/Condition
Allowed	Adults and adolescents 12 years of age and older.
Contraindicated	Severe hepatic impairment or active liver disease.
Contraindicated	Known hypersensitivity to Acetaminophen, Chlorzoxazone, or any component.
Contraindicated	Children under 12 years of age.
Contraindicated	Concurrent use of any other acetaminophen-containing medicine.
Not Recommended	Pregnancy and Lactation.

The official eligibility profile is structured around these absolute restrictions. Use is formally prohibited for individuals with severe liver dysfunction, specific allergies, and those concurrently consuming other acetaminophen products due to the risk of exceeding the safe daily limit. The combination is generally not established for use in children under 12. Regulatory caution is also advised for older adult patients and those with renal impairment, reflecting the need for medical consideration when organ function may be compromised.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Tafirol Flex, which contains Acetaminophen (Paracetamol) and Chlorzoxazone, focuses on metabolic risks and pharmacodynamic reinforcement.

Contraindicated Combinations

Co-administration with other acetaminophen-containing products is strictly restricted to prevent accidental overdose and the resulting potential for acute liver failure.

Clinically Significant Interactions

Additive Central Nervous System (CNS) Depression: The Chlorzoxazone component poses a risk of additive pharmacodynamic effects when combined with other CNS Depressants (including opioids, benzodiazepines, and certain antidepressants). This is documented to increase the risk of severe sedation and impaired mental alertness.

Anticoagulants: Chronic, high-dose use of the acetaminophen component is officially stated to increase the International Normalized Ratio (INR) in patients taking Warfarin (Sodium Warfarin), which reflects an alteration of the anticoagulant effect.

Hepatotoxicity Risk: The risk of severe liver injury from the acetaminophen component is formally documented to increase with co-exposure to substances that induce or regulate the hepatic enzyme CYP2E1. This includes alcohol (ethanol), which also contributes to additive CNS depression with Chlorzoxazone.

Population-Specific Cautions

Interaction severity is heightened in specific populations. The acetaminophen component is contraindicated in severe hepatic impairment, and caution is required for the chlorzoxazone component in patients with preexisting liver disease. Chronic alcohol users also face an officially increased risk of hepatotoxicity.

Mechanism of Action

Mechanism of Action: How Tafirol Flex Works

Tafirol Flex contains two active ingredients that influence separate biological pathways: central modulation of nociception and reduction of efferent motor signaling.

The Paracetamol component acts primarily within the central nervous system (CNS). Its mechanism involves the influence of key enzymes such as Cyclooxygenase (COX) and the activation of pathways including the TRPV1 receptor. This inhibition and modulation reduce the synthesis of prostaglandins and enhance descending inhibitory signals, resulting in an elevated central threshold for nociception and modulation of the hypothalamic temperature set-point.

The Pridinol component works as an antagonist at muscarinic acetylcholine receptors (mAChRs) in the spinal cord and brainstem. By blocking the binding of the excitatory neurotransmitter acetylcholine, it suppresses efferent motor nerve signaling. This leads to a reduction in skeletal muscle resting tone and reflex activity.

The simultaneous influence on both nociception pathways and motor signaling pathways results in the modulation of peripheral muscle resting tone and central pain perception.

Dosage and Administration Information

Tafirol Flex is administered strictly via the oral route as a solid tablet. The usage protocol establishes that the medicine is primarily intended for short-term use as an adjunct to rest and physical therapy for acute conditions.

The standard adult regimen involves taking divided doses three or four times daily, which corresponds to maintaining an approximate six-to-eight-hour interval between administrations. The dose of the Chlorzoxazone component usually begins in the 250 mg to 500 mg range and may be adjusted up to a maximum of 750 mg per dose, with instructions to reduce the dose as symptomatic improvement is observed.

A fundamental administrative constraint is the absolute daily limit on the Acetaminophen component: the total intake from all sources must not exceed 4,000 mg (4 grams) to avoid toxicity. Regarding intake conditions, the tablets may be taken with or immediately following a meal to help mitigate potential gastrointestinal discomfort. Dose adjustments are a required principle for patients with existing hepatic impairment. Standard dosing for the pediatric population is typically not established in official labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tafirol Flex

Tafirol Flex is a fixed-dose combination medicine containing Acetaminophen and Chlorzoxazone. The clinical evidence available for this medicine comes primarily from studies and reviews that have explored patterns related to its active components, either alone or in combination with other agents, during periods of heightened symptom activity associated with muscle discomfort. The research available contributes to understanding what has been observed so far in controlled study settings.

Research Examining Acute Painful Musculoskeletal Injuries (Non-Spinal)

Research for this combination has primarily relied on short-term Randomized Controlled Trials (RCTs) that were applied in studies examining patient-reported experiences. Research examined the medicine in adult patients presenting with acute injuries like muscle strains or sprains during periods of increased symptom activity. Researchers designed these trials to monitor physiological strain or stress. Specifically, studies explored outcomes related to physical discomfort using standardized scales, and studies monitored outcomes reflecting daily functioning or activity level.

The available evidence contributes to understanding symptom patterns, with some trials describing patterns such as how symptoms evolved in the observed populations in pain scores when compared to a non-active treatment. However, the existing evidence is limited and often described in scientific analyses as having a low certainty rating. The findings describe group patterns, not personal outcomes, and research provides insight into short-term changes only.

Research Examining Low Back Pain and Myofascial Pain Syndromes

Research has also examined the combination's components in conditions characterized by fluctuating or episodic manifestations, such as acute low back pain and certain Myofascial Pain Syndromes. In this context, studies often focused on Fixed-Dose Combinations (FDCs) that included both Acetaminophen and Chlorzoxazone, alongside a third medicine, such as a nonsteroidal anti-inflammatory drug (NSAID). Research explored outcomes related to physical discomfort and changes in muscle rigidity, using methods like assessing flexibility.

Research describes patterns related to pain severity and flexibility that were observed in some studies when the combinations were evaluated in contexts involving comparator agents. However, research describes that the data for the specific two-drug combination (Tafirol Flex) in low back pain is often indirect, relying heavily on the results of studies that included that third active component. Therefore, comparative evidence is lacking between the two-drug and three-drug combinations.

Long-Term Studies and Follow-Up Data

The majority of research examined short-term symptom patterns, having been conducted over brief observation periods. Long-term effects are not fully established; evidence contributes to understanding symptom patterns only. Data for long-term outcomes remain insufficient.

What Research Still Defines as Uncertain

The current research contributes to the broader evidence landscape but highlights several known limitations and areas of uncertainty. Evidence quality varies across studies, and scientific reviews often note that the certainty remains low for the direct two-drug combination in some contexts. The evidence landscape includes studies of related three-drug FDCs in conditions like low back pain; comparative evidence is lacking, and some subgroup findings appear to be uncertain. Research is ongoing, but data are still emerging regarding research scenarios involving other agents. This evidence highlights what is known—and what is still uncertain—about this specific fixed-dose preparation.

Key Studies & References

F. No. 04-146/2007-DC - Government of India - Directorate General of Health Services (CDSCO)

Frequently Asked Questions (FAQ)

Common questions about Tafirol Flex (FAQ)

Q: How long does the relief from Tafirol Flex usually last?

Official information regarding the muscle relaxant component, chlorzoxazone, indicates a documented duration of action of approximately 3 to 4 hours. This component has a short elimination half-life of about 1.1 hours. The overall duration of relief may also be influenced by the ongoing effects of the analgesic component.

Q: Are there any common foods or drinks that interact with Tafirol Flex?

Alcohol is the primary, clinically significant drink that interacts, as official warnings state it increases the risk of liver damage and central nervous system effects. Regulatory documents indicate the tablets may be taken with or without food. Taking the medication immediately following a meal can sometimes help to mitigate potential stomach upset.

Q: Is Tafirol Flex safe for people with a history of stomach issues?

The muscle relaxant component, chlorzoxazone, has been associated with rare instances of gastrointestinal bleeding. In contexts involving severe GI history, the use of muscle relaxant combinations may require cautious evaluation. Patients with a history of serious stomach or intestinal problems are advised to discuss their history with a healthcare professional.

Q: What distinguishes Tafirol Flex from a simple NSAID (like ibuprofen)?

Tafirol Flex is a fixed-dose combination (FDC) of an analgesic (Acetaminophen) and a skeletal muscle relaxant (Chlorzoxazone). Simple NSAIDs are anti-inflammatory medications that work differently. The muscle relaxant component of Tafirol Flex acts centrally on the spinal cord to reduce muscle spasm, a mechanism that NSAIDs do not share.

Q: What is the general safety classification of Tafirol Flex?

The muscle relaxant component, chlorzoxazone, is formally classified as a Prescription-only drug in the United States. This component is not listed as a controlled substance by the Drug Enforcement Administration (DEA), meaning it does not have a formal abuse or dependence schedule.

Q: What is the dual purpose of this combination medicine?

Official product information indicates that this medicine is used as an adjunct to rest and physical therapy for acute, painful musculoskeletal conditions. The two components are combined because they simultaneously address both components of discomfort: pain (via the analgesic) and muscle tension (via the skeletal muscle relaxant).

Q: How does Tafirol Flex affect sleep?

The muscle relaxant component is known to commonly cause drowsiness or somnolence as a frequent central nervous system side effect. Regulatory labeling cautions against engaging in activities that require complete mental alertness, such as driving, until the medicine's effect on the user is understood.

Q: Is the onset time of Tafirol Flex affected by food?

The medication may be taken with or without food, according to official instructions, as food is mainly recommended to help mitigate potential gastrointestinal discomfort. Regulatory information on the muscle relaxant component indicates peak blood levels are typically reached within approximately 1 to 2 hours after administration.

Q: How quickly do people typically start to feel the effects of Tafirol Flex?

The muscle relaxant component, chlorzoxazone, is absorbed relatively quickly. Regulatory pharmacokinetic data indicates the component can be detected in the blood within the first 30 minutes after oral administration, with peak levels typically reached within 1 to 2 hours.

Q: Is Tafirol Flex habit-forming or addictive?

The muscle relaxant component, chlorzoxazone, is not listed as a controlled substance by the Drug Enforcement Administration (DEA). Therefore, it does not have a formal regulatory schedule for abuse or dependence.

Q: Is Tafirol Flex safe to take with common vitamins or supplements?

Official advice focuses on the importance of disclosing all drugs, vitamins, and supplements to a healthcare professional. This is because some common supplements and certain high-dose vitamins may have documented interactions with the active ingredients.

Q: Can people with high blood pressure use Tafirol Flex?

Caution is typically advised when prescribing muscle relaxant combinations to patients with underlying conditions such as heart disease or high blood pressure. This reflects the need for medical consideration when organ function may be compromised.

Q: Is Tafirol Flex available over the counter, or is it prescription-only?

While the active ingredients are regulated differently depending on the country, the muscle relaxant component, chlorzoxazone, is generally classified as a Prescription-only drug in the United States and similar regulatory markets.

Q: Can Tafirol Flex be used for headaches or migraines?

The medicine is primarily indicated for acute painful musculoskeletal conditions where muscle spasm is present. Regulatory and clinical summaries state the muscle relaxant component is sometimes administered for conditions such as tension headache (muscle contraction headache).

Q: Is there a generic version of Tafirol Flex available?

The two active ingredients, Acetaminophen and Chlorzoxazone, are both available in generic tablet forms in the United States and other markets.

Q: Can Tafirol Flex affect a person's mood or energy levels?

Official regulatory documents list several central nervous system-related side effects. These may include malaise (a general feeling of discomfort or illness), fatigue, and, in rare instances, mental/mood changes.

Q: Are there any known interactions between Tafirol Flex and common herbal remedies?

Yes, official documentation states that certain herbal supplements can interact with the active ingredients. For example, supplements including Ginseng and Kava are documented to interact with the medicine's components. Official safety information highlights the importance of disclosing all supplements to a healthcare professional.

How should Tafirol Flex be stored and disposed of?

How to Store and Dispose of Tafirol Flex?

This medication must be kept in its original container with the safety cap securely closed. Store it at room temperature in a cool, dry place, away from excessive heat, moisture, and direct light, and strictly out of the sight and reach of children.

The most recommended method for disposing of unused or expired medicine is through a drug take-back program, such as community collection events or permanent disposal sites (e.g., at certain pharmacies or police stations).

If a take-back program is not available and the medication's label does not specify flushing, dispose of it in the household trash. To do this, mix the tablets (do not crush them) with an undesirable substance like dirt, used coffee grounds, or cat litter. Place this mixture into a sealed bag or container, and then discard it in the trash. Before disposal, scratch out all personal information on the prescription label.

Tafirol Flex